Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of non-ATP competitive FGFR1 inhibitor and its application

A technology of FGFR1 and inhibitor, applied in the field of pharmacy, can solve the problems of large toxic and side effects, poor targeting selectivity, etc.

Active Publication Date: 2020-12-04
WENZHOU MEDICAL UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

About 518 tyrosine receptor kinases encoded in the human genome share a highly conserved ATP-binding domain, which leads to poor targeting selectivity of competitive inhibitors and greater toxic side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of non-ATP competitive FGFR1 inhibitor and its application
  • A kind of non-ATP competitive FGFR1 inhibitor and its application
  • A kind of non-ATP competitive FGFR1 inhibitor and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] The synthesis of embodiment 1 compound

[0024] Dissolve 1mmol of the corresponding terephthalaldehyde and 2mmol of substituted acetophenone in about 20mL of absolute ethanol, add 10-15 drops of 50% NaOH solution at 5-8°C, react for 5-24h at 5-8°C, and use The progress of the reaction was detected by TLC. After the reaction, add 1-2 times the volume of the reaction solution in water to precipitate precipitates, filter, and vacuum dry overnight to obtain a powder product, which is purified by silica gel column chromatography to obtain compounds with a purity greater than 98%. Among the multiple compounds synthesized, the pharmacological activities vary greatly, and the representative compounds and their physicochemical properties are as follows:

[0025] Effective compound (2E,2'E)-3,3'-(1,4-phenylene)bis(1-(2-chlorophenyl)prop-2-en-1-one)(L16H50)Yellow powder,90.2%yield ,mp144.4~147.1℃.ESI-MS m / z:407.0(M+1) + calcd for C 24 h 16 Cl 2 o 2 :407.29. 1 H-NMR (DMS O)...

Embodiment 2

[0028] The inhibitory activity of embodiment 2 compound to FGFR1 kinase

[0029] The Caliper EZ reader drug screening platform was used to detect the kinase activity of the compound on FGFR1. Set the concentration of ATP at the Km value of FGFR1, which is 262 μmol / mL. In order to detect the IC of the compound against the kinase inhibitory activity 50 , the compound was diluted into 10 concentration gradients from 5 nmol / mL to 100 μmol / mL. During mobility detection, the accumulated amount of product is represented by conversion rate=A / (A+B), where A represents the peak height of the product, and B represents the peak height of the substrate. IC of L16H50 for kinase inhibitory activity 50 For: 3.8±2.7μM; while the inhibition rates of the control compounds L15H50 and L20H50 at the concentration of 100μmol / mL to FGFR1 kinase were 19.5% and 15.8%, respectively, it can be considered that both are not FGFR1 kinase inhibitors.

Embodiment 3

[0030] Example 3 L16H50 inhibits FGFR1 kinase activity in a non-ATP competitive manner

[0031] L16H50 is a new type of FGFR1 kinase inhibitor. In order to explore its inhibitory mode on FGFR1 kinase, its competitive relationship with ATP was determined. Specific method: first fix the concentration of the substrate (a sufficient concentration relative to the kinase), then add a certain amount of kinase, and then add different concentrations of ATP (5000, 2500, 1250, 625, 312.5, 156.25, 78.125 and 39.0625μmol / mL) and compounds (L16H50: 100, 50, 25, 13, 6.5, 3.3, 1.6, 0.8, 0.4 and 0.2μmol / mL), and then determine the kinase to substrate under different concentrations of ATP and compound conditions Conversion rate, according to the formula conversion rate = (Vmax*X) / {km*[(1+I / Ki) n ]+X}. X represents the concentration of ATP, and n represents the Hill coefficient. See the experimental results figure 1 D, the results show that at a fixed L16H50 concentration, the substrate conv...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of pharmacy and particularly relates to application of a specific non-ATP-competiveness FGFR1 (fibroblast growth factor receptor 1) inhibitor in preparing anticancer medicine and medicine for treating cancer-related diseases. The invention further relates to a small molecule compound L16H50 which can inhibit FGFR1 and activation of a signal channel of the FGFR1 in a non-ATP-dependent mode. Therefore, multiplication and survival of cancer cells are inhibited, and good in-vitro and in-vivo anticancer effects are further given to play.

Description

technical field [0001] The present invention belongs to the field of pharmacy. Specifically, the present invention relates to a small molecular compound that can inhibit the activation of FGFR1 and its signaling pathway in an ATP-independent manner, thereby exerting good anti-tumor effects in vivo and in vitro. Background technique [0002] FGFR1, namely fibroblast growth factor receptor 1, is a member of the fibroblast growth factor (FGF) family and belongs to the tyrosine receptor kinase. A large number of studies have proved that FGFR1 is closely related to a variety of tumors, such as gastric cancer. In gastric cancer, the expression of FGFR1 is related to the 10-year survival rate and distant metastasis of tumors. Such as lung cancer, studies have shown that the expression of FGFR1 can be used as a prognostic marker for non-small cell lung cancer. In breast cancer, amplification of the region of chromosome 8p11-12 (and the region where FGFR1 is located) occurs in 10% o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07C49/813A61K31/12A61P35/00
CPCC07C49/813
Inventor 吴建章李物兰梁广杜晓静
Owner WENZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com